Shamima Chowdhury, MD
Internal Medicine · Mount Vernon, NYNPI 1154589026
Payments from drug & device makers
Across 267 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$795
- Amgen$689
- Philips North America LLC$407
- Merck$384
- AstraZeneca$259
- Lilly USA, LLC$237
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,997100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $795 |
| Amgen | 24 | $689 |
| Philips North America LLC | 26 | $407 |
| Merck | 27 | $384 |
| AstraZeneca | 15 | $259 |
| Lilly USA, LLC | 16 | $237 |
| Pfizer | 14 | $225 |
| AbbVie | 13 | $214 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $191 |
| Sanofi-aventis U.S. LLC | 11 | $159 |
| Madrigal Pharmaceuticals | 1 | $148 |
| Exact Sciences | 6 | $145 |
| Viatris Specialty LLC | 7 | $130 |
| Actelion Pharmaceuticals US, Inc. | 5 | $130 |
| Kowa Pharmaceuticals America, Inc. | 1 | $125 |
| GSK | 6 | $88 |
| Collegium Pharmaceutical, Inc. | 6 | $84 |
| Mannkind Corporation | 4 | $63 |
| Boehringer Ingelheim | 4 | $62 |
| Amarin Pharma, Inc. | 4 | $55 |
| Ardelyx, Inc. | 3 | $53 |
| Abbott | 2 | $49 |
| Mylan Specialty L.p. | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Hikma Pharmaceuticals USA | 2 | $38 |
| Johnson & Johnson | 2 | $36 |
| Novartis | 2 | $29 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,018 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $127,726 |
| JardianceEmpagliflozin | 158 | $125,231 |
| FarxigaDapagliflozin Propanediol | 154 | $123,436 |
| JanuviaSitagliptin Phosphate | 104 | $92,488 |
| TrulicityDulaglutide | 39 | $50,241 |
| EliquisApixaban | 87 | $48,050 |
| ProliaDenosumab | 16 | $29,059 |
| MounjaroTirzepatide | 28 | $28,516 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $26,236 |
| TradjentaLinagliptin | 28 | $21,207 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $13,975 |
| LinzessLinaclotide | 20 | $11,785 |
| VascepaIcosapent Ethyl | 38 | $11,282 |
| CreonLipase/Protease/Amylase | 14 | $9,552 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $7,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $62 | $146,438186 claims |
| AstraZenecaFarxiga, Lokelma, Symbicort | $259 | $132,932177 claims |
| Novo NordiskOzempic | $795 | $127,726132 claims |
| MerckJanuvia, Janumet | $384 | $118,724134 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $237 | $78,75767 claims |
| PfizerEliquis | $225 | $48,05087 claims |
| AmgenProlia | $689 | $29,05916 claims |
| AbbVieLinzess, Creon | $214 | $21,33734 claims |
| GSKTrelegy Ellipta | $88 | $13,97523 claims |
| NovartisEntresto | $29 | $4,81414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Mount Vernon
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.